Gerd Birkenmeier; Silke Nicklisch; Christiane Pockelt; etal
(2006)
A drug targeting both the inflammatory initiators (lipopolysaccharide; LPS) and mediators [tumor necrosis factor- (TNF- )]
should have advantage over a “single-factor targeting strategy”
in sepsis prevention trials. We ...